When is radiopharmaceutical therapy most appropriately initiated in men with mCRPC?

Posted on November 21, 2013 by Sitemaster

A newly published paper by a team of Italian researchers has added a wrinkle to the critical questions about the most effective current and future forms of sequential therapy for men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , , , , , , | Leave a comment »

Full data report from the ALSYMPCA trial of radium-223 presented

Posted on September 26, 2011 by Sitemaster

According to a company media release, the full results of the ALSYMPCA  trial were presented Saturday at the European Multidisciplinary Cancer Congress (EMCC). This is the trial of the injectable radioactive agent radium-223 chloride (Alpharadin®) in men with symptomatic, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Filed under: Drugs in development, Management, Treatment | Tagged: , , , , | Leave a comment »

  • Donate

  • Disclaimer

    News and information provided on this site should not be used for diagnosing or treating any health problem or disease.

    The “New” Prostate Cancer InfoLink is intended for informational purposes only. It is not engaged in rendering medical advice or professional services and is not a substitute for professional care. If you have or suspect you may have a health problem, please consult your healthcare provider.

  • Hot Posts …

  • … and Archives